Rani Therapeutics Holdings, Inc. Class A Common Stock (RANI) Stock Price

RANIStock

$0.64+36.01%52W

Market Cap$90.02M

P/E—

PEG Ratio—

Div yield—

Beta0.72

RANI Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-33.40%

Price vs S&P 500 (4W)-17.52%

VGM Score59.17

Book Value / Share (Quarterly)$0.29

P/TBV (Annual)2.73x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-15.64%

Cash Flow / Share (Quarterly)$-0.15

Price vs S&P 500 (YTD)-64.47%

Net Profit Margin (TTM)-507.05%

EPS (TTM)$-0.26

10-Day Avg Trading Volume0.61M

EPS Excl Extra (TTM)$-0.26

Revenue Growth (5Y)10.75%

EPS (Annual)$-0.45

ROI (Annual)-89.89%

Net Profit Margin (5Y Avg)-2277.42%

Cash / Share (Quarterly)$0.39

Revenue Growth QoQ (YoY)893.02%

ROA (Last FY)-50.62%

Revenue Growth TTM (YoY)306.42%

EBITD / Share (TTM)$-0.23

ROE (5Y Avg)-392.26%

Operating Margin (TTM)-538.81%

Cash Flow / Share (Annual)$-0.15

P/B Ratio2.28x

P/B Ratio (Quarterly)2.64x

Net Income / Employee (Annual)$-430,000

EV / Revenue (TTM)17.31x

Net Interest Coverage (TTM)-18.84x

ROA (TTM)-66.43%

EPS Incl Extra (Annual)$-0.45

Current Ratio (Annual)4.21x

Quick Ratio (Quarterly)5.25x

3-Month Avg Trading Volume0.72M

52-Week Price Return36.01%

Revenue / Employee (TTM)$70,700

Tangible BV / Share (Quarterly)$0.35

P/S Ratio (Annual)54.68x

Asset Turnover (Annual)0.03x

52-Week High$3.87

Operating Margin (5Y Avg)-3169.63%

EPS Excl Extra (Annual)$-0.45

CapEx CAGR (5Y)-40.70%

26-Week Price Return-23.49%

Quick Ratio (Annual)4.08x

13-Week Price Return-8.13%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)5.31x

Enterprise Value$84.43M

Revenue / Share Growth (5Y)3.90%

Asset Turnover (TTM)0.09x

Revenue / Employee (Annual)$23,700

Pretax Margin (Annual)-2507.65%

Cash / Share (Annual)$0.41

3-Month Return Std Dev86.11%

Net Income / Employee (TTM)$-436,800

ROE (Last FY)-89.89%

Net Interest Coverage (Annual)-15.61x

EPS Basic Excl Extra (Annual)$-0.45

Receivables Turnover (TTM)4.78x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-0.26

ROI (TTM)-73.71%

P/S Ratio (TTM)18.31x

Pretax Margin (5Y Avg)-3259.90%

Revenue / Share (Annual)$0.02

Tangible BV / Share (Annual)$0.75

Price vs S&P 500 (52W)20.48%

Year-to-Date Return-52.55%

5-Day Price Return-14.69%

EPS Normalized (Annual)$-0.45

ROA (5Y Avg)-45.25%

Net Profit Margin (Annual)-1817.09%

Month-to-Date Return-19.01%

Cash Flow / Share (TTM)$-2.79

EBITD / Share (Annual)$-0.57

Operating Margin (Annual)-2381.26%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-69.41%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-0.26

P/TBV (Quarterly)5.73x

P/B Ratio (Annual)4.97x

Pretax Margin (TTM)-523.07%

Book Value / Share (Annual)$0.27

Price vs S&P 500 (13W)-10.82%

Beta0.72x

Revenue / Share (TTM)$0.03

ROE (TTM)-73.71%

52-Week Low$0.46

vGradeD

gGradeA

mGradeC

vgmGradeC

RANI Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 13, 2026	-$0.05	-$0.04	+20.00%(+$0.01)
Q1 2026	May 15, 2026	-$0.04	-$0.04	+7.69%(+$0.00)
Q4 2025	Mar 26, 2026	-$0.07	-$0.07	-4.99%(-$0.00)
Q3 2025	Nov 6, 2025	-$0.12	-$0.12	+2.70%(+$0.00)
Q2 2025	Aug 7, 2025	-$0.20	-$0.18	+7.69%(+$0.02)

RANI Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

4.10

4.09

Industry Peers — Pharmaceuticals(574)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
RANIRani Therapeutics Holdings, Inc. Class A Common Stock	D	A	C	18.3x	306.4%	—	—	$0.64
LLYEli Lilly & Co.	D	B	A	14.9x	49.6%	83.4%	27.6%	$1257.03
JNJJohnson & Johnson	D	C	B	6.2x	7.8%	67.7%	14.9%	$255.56
ABBVABBVIE INC.	D	C	A	7.8x	10.4%	72.8%	-2.9%	$285.42
MRKMerck & Co., Inc.	D	C	A	5.4x	4.6%	77.3%	21.2%	$145.95
NVSNovartis AG	C	C	B	4.9x	3.3%	75.0%	15.3%	$150.62
AZNAstraZeneca PLC	C	B	B	4.3x	8.6%	81.3%	21.9%	$165.41
ABTAbbott Laboratories	C	C	B	3.9x	8.1%	56.8%	8.2%	$104.89
NVONovo-Nordisk A/S	B	C	C	3.5x	5.6%	80.7%	20.7%	$38.83
PFEPfizer Inc.	C	D	A	2.6x	-0.2%	74.7%	-3.5%	$29.58
VRTXVertex Pharmaceuticals Inc	D	C	B	10.1x	10.2%	86.0%	8.3%	$499.74
BMYBristol-Myers Squibb Co.	B	B	B	2.5x	3.1%	71.7%	—	$59.75
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	C	C	B	2.3x	5.0%	73.6%	-0.5%	$49.51
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	D	B	1.8x	13.4%	72.8%	-8.2%	$40.61
REGNRegeneron Pharmaceuticals Inc	C	C	A	5.2x	9.3%	86.0%	6.3%	$790.74
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	A	2.1x	3.1%	65.5%	-12.6%	$19.67
TEVATeva Pharmaceutical Industries Limited	D	C	A	2.8x	4.1%	52.9%	—	$41.50
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	6.3x	31.1%	88.5%	—	$369.06
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	A	13.8x	10.0%	—	-12.1%	$60.96
ZTSZOETIS INC.	C	C	B	3.5x	1.4%	71.6%	12.0%	$79.38
ALNYAlnylam Pharmaceuticals, Inc.	D	A	C	6.5x	95.1%	79.7%	—	$231.83
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	3215.5x	-67.6%	81.2%	—	$33.53
UTHRUnited Therapeutics Corp	C	C	B	7.2x	2.5%	86.1%	19.3%	$533.12
GMABGenmab A/S ADS	D	C	A	5.5x	22.3%	93.0%	6.8%	$37.00
VTRSViatris Inc. Common Stock	B	C	A	1.5x	4.4%	40.3%	—	$18.66
INSMInsmed, Inc.	F	A	C	18.5x	185.8%	83.5%	—	$96.27
ASNDAscendis Pharma A/S Ordinary Share	D	A	B	11.9x	113.3%	91.3%	—	$225.25
JAZZJazz Pharmaceuticals, Inc.	B	C	B	3.0x	12.6%	88.4%	-1.4%	$210.23
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	18.2x	202.4%	94.4%	—	$66.39
CORTCorcept Therapeutics Inc.	F	C	A	14.3x	16.0%	98.3%	-0.5%	$110.16
ELANElanco Animal Health Incorporated Common Stock	D	B	B	2.3x	11.9%	55.4%	29.9%	$23.55
SMMTSummit Therapeutics Inc. Common Stock	F	—	C	12187.5x	—	—	—	$14.63
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	C	B	3.1x	-0.9%	61.4%	16.5%	$13.07
BMRNBioMarin Pharmaceuticals Inc	C	C	B	3.1x	11.2%	79.6%	-17.0%	$54.68
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	8.1x	149.0%	91.5%	—	$449.74
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	213.8x	2928.4%	—	—	$84.95
CYTKCytokinetics Inc.	F	D	B	127.3x	-21.1%	—	—	$61.95
PTGXProtagonist Therapeutics, Inc	F	B	B	29.5x	34.8%	—	—	$128.75
TGTXTG Therapeutics, Inc.	D	B	B	10.3x	76.1%	82.4%	—	$53.97
AXSMAxsome Therapeutics, Inc	D	B	C	10.6x	56.9%	93.2%	—	$157.14
ARWRArrowhead Research Corporation	D	A	C	11.8x	16.9%	—	—	$55.90
ABVXAbivax SA American Depositary Shares	—	—	C	—	—	—	—	$88.13
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	5995.2x	—	—	—	$79.90
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	8.2x	-7.5%	98.2%	—	$42.94
ALKSAlkermes Inc. plc	D	C	B	4.1x	10.8%	84.6%	—	$41.22
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	789.2x	—	—	—	$241.76
AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock	D	C	A	2.0x	9.3%	39.3%	-18.4%	$19.18
KNSAKiniksa Pharmaceuticals International, plc Class A Ordinary Shares	D	B	A	7.3x	58.9%	89.8%	—	$78.59
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	24.7x	53.5%	70.9%	—	$86.17
LGNDLigand Pharmaceuticals Inc.	D	B	B	20.3x	54.9%	95.4%	—	$295.54
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	—	—	—	—	$142.78

About Rani Therapeutics Holdings, Inc. Class A Common Stock

Rani Therapeutics is a clinical-stage biotherapeutics company developing the RaniPill platform to deliver biologics such as antibodies, proteins, peptides, and oligonucleotides orally instead of by injection. The proprietary technology aims to provide patients and healthcare systems with a more convenient alternative to painful subcutaneous or intravenous injections. The company is also advancing RaniPill HC to enable delivery of liquid drug payloads with high bioavailability.

RANI Next Earnings Report

Report dateNov 5, 2026

QuarterQ3 2026

Report timeAMC

EPS estimate-$0.05

Revenue estimate$1.28M

Also reporting on Nov 5, 2026

Scheduled date with consensus estimates — both can change before the company reports.

Earnings calendar for November 2026

RANI Insider Transactions

BuyJul 21, 2026
IMRAN MIR A
Director and Beneficial Owner of more than 10% of a Class of Security
Shares: 36,000Value: $24,840

Open-market buys and sells filed with the SEC over the last 90 days. Grants, gifts and option exercises are excluded.

All insider transactions for July 2026

Companies in Related Industries

BDTXBlack Diamond Therapeutics, Inc. Common StockBiological Products
IMDXInsight Molecular Diagnostics Inc. Common StockIn Vitro Diagnostics
ICCCImmucell CorpIn Vitro Diagnostics
ATRAAtara Biotherapeutics, IncBiological Products
NMRANeumora Therapeutics, Inc. Common StockBiological Products
TNYATenaya Therapeutics, Inc. Common StockBiological Products
GRMLGreenland Mines Ltd. Common StockBiological Products
FTLFFitLife Brands, Inc. Common StockPharmaceutical Preparations

Same SIC sector, outside this company's own industry.

Analyst Sentiment

4.1

Buy

Consensus rating

52-Week Range

Low$0.46

High$3.87